Inhibitors of multidrug resistance transporter p-glycoprotein
The present disclosure provides a method of treating a subject that is resistant to one or more drugs by identifying a subject having one or more drug resistant cells; administering to the subject a pharmaceutically effective amount of an inhibitor compound, and contacting one or more drug resistant cells with the inhibitor compound to reduce the export of the inhibitor compound from the one or more drug resistant tumor cells and to block the transport of drug(s) from the one or more drug resistant cells.
1. A method of decreasing a P-glycoprotein activity of a cancer cell in a cancer patient, wherein the cancer cell has built up resistance to a therapeutically active agent comprising the steps of:
administering to the cancer patient before further treatment, during treatment or after treatment with the therapeutically active agent, an amount of an inhibitor compound having one of the following structural formulas:
in an amount that blocks the transport of the therapeutically active agent from one or more cancer cells of the cancer patient by the P-glycoprotein.
2. The method of claim 1 , wherein the inhibitor compound interacts with an exporter protein.
3. The method of claim 1 , wherein the inhibitor compound is a P-glycoprotein inhibitor.
4. The method of claim 1 , wherein the inhibitor compound interacts with drug-toxin pumping structures of a P-glycoprotein.
5. The method of claim 1 , wherein the inhibitor compound interacts with ATP binding domain(s) of a P-glycoprotein and the inhibitor compound does not bind to drug binding site(s) on the P-glycoprotein.
6. The method of claim 1 , wherein the inhibitor compound is minimally transported by a P-glycoprotein.
7. The method of claim 1 , wherein the cancer cells express a P-glycoprotein and are one or more multidrug resistant tumor cells.
8. The method of claim 1 , wherein the cancer cells express a P-glycoprotein and are lymphoma, leukemia, cancer stem cells, nonsmall-cell lung cancer, liver cancer, encephaloma, leukocythemia, carcinoma of prostate, intestine cancer, myeloma tumor, lymphoma, breast carcinoma, ovarian cancer, gastric cancer, small cell lung cancer, esophageal carcinoma, esophageal carcinoma, and sarcoma.
9. The method of claim 1 , further comprising the step of administering one or more chemotherapeutic agents to the subject.
10. The method of claim 1 , wherein the inhibitor compound is effective for at least one of: increasing the effectiveness of the chemotherapeutic drug to inhibit proliferation, inducing cell death, or indirectly inhibiting development of a tumor by suppressing tumor angiogenesis, reducing the export of the inhibitor compound from the one or more drug resistant tumor cells, to block the transport of chemotherapeutic drug(s) from the one or more drug resistant cancer cells, or increasing an efficacy of one or more chemotherapeutics and/or decreasing toxicity of the chemotherapeutic treatment(s).